Literature DB >> 31146120

Excessive expressions of T cell activation markers in pediatric immune thrombocytopenia.

Yuanyuan Chen1, Yanqiong Zhou1, Ping Chen1, Ping Zhang1, Ming Jia1, Yongmin Tang2.   

Abstract

BACKGROUND: Immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder in children. Activated T cells have been shown to play important roles in ITP. The aims of this study were to evaluate whether these T cell activation markers could be used as indicators to differentiate ITP patients from controls, and to assess whether they could be used as predictors of IVIG response in ITP patients.
METHODS: A cohort of 92 hospitalized ITP patients, 49 unrelated healthy children, and 48 thrombocytosis patients were enrolled in this retrospective study between February 2013 and September 2018. Expression of CD25, HLA-DR, and CD69 on the surfaces of CD4+ and CD8+ T cells were detected by flow cytometry. All statistical analyses were performed using SPSS 20.0 software.
RESULTS: Compared to the healthy controls, ITP patients had higher percentages of CD4 + CD25+ T cells, CD4 + HLA-DR+ T cells, CD8 + HLA-DR+ T cells, and CD8 + CD69+ T cells. Compared to the thrombocytosis patients, ITP patients had higher percentages of CD4 + HLA-DR+ T cells and CD8 + HLA-DR+ T cells, and lower CD4 + CD69+ T cells and CD8 + CD69+ T cells. Platelet count at admission had a negative correlation with CD4 + CD25+ T cells in ITP. CD4 + CD69+ T cells were decreased in chronic compared to the newly diagnosed and persistent ITP patients. Activated T cell markers had no predictive value for IVIG response in ITP patients.
CONCLUSIONS: T cell activation markers were excessively expressed in pediatric ITP, and those markers had no predictive value for IVIG response in ITP patients.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD25; CD69; Children; HLA-DR; Immune thrombocytopenia

Mesh:

Substances:

Year:  2019        PMID: 31146120     DOI: 10.1016/j.thromres.2019.05.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia.

Authors:  Sheng-Hong Du; Yu-Jiao Xiang; Lu Liu; Mu Nie; Yu Hou; Ling Wang; Ban-Ban Li; Miao Xu; Qing-Liang Teng; Jun Peng; Ming Hou; Yan Shi
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

2.  Activin a suppresses peripheral CD8+ T lymphocyte activity in acute-phase Kawasaki disease.

Authors:  Qian Wu; Ruohang Weng; Yongbin Xu; Linlin Wang; Yanyan Huang; Jun Yang
Journal:  BMC Immunol       Date:  2021-02-23       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.